Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Results 14 years later

  • J. P. Dutcher
  • P. H. Wiernik
Part of the Developments in Oncology book series (DION, volume 32)


Although extended field radiotherapy can cure most patients with Hodgkin’s disease confined to lymph nodes, a significant number of potentially curable patients given radiotherapy alone relapse and ultimately die of their disease. Combination chemotherapy produces complete remission and prolonged disease-free survival in the majority of patients with advanced disease [1–4]. This study was initially designed following a pilot investigation which demonstrated the feasibility of a combined modality approach to the treatment of early Hodgkin’s disease, confined to lymph nodes [5, 6]. We are reporting 14 years of follow-up data from this study [7], begun at the Baltimore Cancer Research Center of the NCI (now the University of Maryland Cancer Center).


Herpes Zoster Small Cell Carcinoma Constrictive Pericarditis Combine Modality Treatment Stage IlIA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DeVita VT Jr, Serpick AA and Carbone PP (1970). Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73: 881–895.PubMedGoogle Scholar
  2. 2.
    DeVita VT Jr, Simon RM, Hubbard SM et al. (1980). Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med 92: 587–595.PubMedGoogle Scholar
  3. 3.
    Coltman Ca Jr. (1980). Chemotherapy of advanced Hodgkin’s disease. Semin Oncol 7: 155–173.PubMedGoogle Scholar
  4. 4.
    Diggs CH, Wiernik PH and Sutherland JC (1981). Treatment of advanced untreated Hodgkin’s disease with SCAB — An alternative to MOPP. Cancer 47: 224–228.PubMedCrossRefGoogle Scholar
  5. 5.
    Brace K, Serpick AA, Block JB et al. (1973). Combination radiotherapy and chemotherapy in the treatment of early Hodgkin’s disease. Oncology 27: 484–489.PubMedCrossRefGoogle Scholar
  6. 6.
    Wiernik PH and Lichtenfeld JL (1975). Combined modality therapy for localized Hodgkin’s disease. A seven year update of an early study. Oncology 32: 208–212.PubMedCrossRefGoogle Scholar
  7. 7.
    Wiernik PH, Gustafson J, Schimpff SC et al. (1979). Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Amer J Med 67: 183–192.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Connell MJ, Wiernik PH, Brace KC et al. (1975). A combined modality approach to the treatment of Hodgkin’s disease. Cancer 35: 1055–1065.PubMedCrossRefGoogle Scholar
  9. 9.
    Ruckdeschel JC, Chang P, Martin RG et al. (1975). Radiation-related pericardial effusions in patients with Hodgkin’s disease. Medicine 54: 245–249.PubMedCrossRefGoogle Scholar
  10. 10.
    Martin RG, Ruckdeschel JC, Chang P et al. (1975). Radiation-related pericarditis. Amer J Cardiol 35: 216–220.PubMedCrossRefGoogle Scholar
  11. 11.
    Applefeld MM, Cole JF and Pollock SH (1981). The late appearance of chronic pericardial disease in patients by radiotherapy for Hodgkin’s disease. Ann Intern Med 94: 338–341.PubMedGoogle Scholar
  12. 12.
    Applefeld MM, Slawson RG, Spicer KM et al. (1982). Long-term cardiovascular evaluation of patients with Hodgkin’s disease treated by mantle radiation therapy. Cancer Treat Rep 66: 1003–1013.PubMedGoogle Scholar
  13. 13.
    Fuks Z, Glatstein E, Marsa GW et al. (1976). Long-term effects of external radiation on the pituitary and thyroid glands. Cancer 37: 1152–1161.PubMedCrossRefGoogle Scholar
  14. 14.
    Schimpff SC, Diggs CH, Wiswell JG et al. (1980). Radiation-related thyroid dysfunction: Implications for the treatment of Hodgkin’s disease. Ann Intern Med 92: 91–98.PubMedGoogle Scholar
  15. 15.
    Schlossberger NM and Wiernik PH (1980). The pulmonary function of post-therapy Hodgkin’s disease patients. Proc Amer Assoc Cancer Res and Amer Soc Clin Oncol 21: 468.Google Scholar
  16. 16.
    Schimpff SC, O’Connell MJ, Greene WH et al. (1973). Infections in 92 splenectomized patients with Hodgkin’s disease. Amer J Med 59: 695–701.CrossRefGoogle Scholar
  17. 17.
    Ruckdeschel JC, Schimpff SC, Smyth AE et al. (1977). Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin’s disease. Amer J Med 62: 77–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Stein RS, Golomb HM, Wiernik PH et al. (1982). Anatomic substages of Stage IIIA Hodgkin’s disease: Follow-up of a collaborative Study. Cancer Treat Rep 66: 733–741.PubMedGoogle Scholar
  19. 19.
    O’Dwyer PJ, Wiernik PH, Stewart MB, and Slawson RG (1985). Treatment of early stage Hodgkin’s disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone. In: Cavalli F, Bonadonna G, and Rozencweig M (Eds). Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances, pp 329–336. Boston: Martinus Nijhoff.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • J. P. Dutcher
    • 1
  • P. H. Wiernik
    • 1
  1. 1.Montefiore Medical CenterAlbert Einstein College of MedicineNew YorkUSA

Personalised recommendations